Pfm Health Sciences, LP Day One Biopharmaceuticals, Inc. Transaction History

Pfm Health Sciences, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$12.72 - $16.03 $692,883 - $873,186	-54,472 Reduced 13.73%	342,172 $4.77 Million
Q2 2024 Aug 14, 2024	BUY	$12.03 - $17.69 $497,957 - $732,242	41,393 Added 11.65%	396,644 $5.47 Million
Q1 2024 May 14, 2024	SELL	$13.56 - $17.46 $12.9 Million - $16.6 Million	-948,324 Reduced 72.75%	355,251 $5.87 Million
Q4 2023 Feb 14, 2024	SELL	$9.68 - $15.37 $8.92 Million - $14.2 Million	-921,023 Reduced 41.4%	1,303,575 $19 Million
Q3 2023 Nov 14, 2023	BUY	$11.22 - $14.86 $12.1 Million - $16 Million	1,077,458 Added 93.93%	2,224,598 $27.3 Million
Q2 2023 Aug 14, 2023	BUY	$11.74 - $14.47 $13.5 Million - $16.6 Million	1,147,140 New	1,147,140 $13.7 Million

181

79.7M

130K

217K

Ticker DAWN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,461,104
Market Cap $901M
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...

Get notified when there are updates to the investment portfolio of Pfm Health Sciences, LP, based on Form 13F filings with the SEC.

Stay updated on Pfm Health Sciences, LP with notifications on news.